1
|
Javidanbardan A, Messerian KO, Zydney AL. Membrane technology for the purification of RNA and DNA therapeutics. Trends Biotechnol 2024; 42:714-727. [PMID: 38212210 DOI: 10.1016/j.tibtech.2023.11.016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/29/2023] [Revised: 11/29/2023] [Accepted: 11/30/2023] [Indexed: 01/13/2024]
Abstract
Nucleic acid therapeutics have the potential to revolutionize the biopharmaceutical industry, providing highly effective vaccines and novel treatments for cancers and genetic disorders. The successful commercialization of these therapeutics will require development of manufacturing strategies specifically tailored to the purification of nucleic acids. Membrane technologies already play a critical role in the downstream processing of nucleic acid therapeutics, ranging from clarification to concentration to selective purification. This review provides an overview of how membrane systems are currently used for nucleic acid purification, while highlighting areas of future need and opportunity, including adoption of membranes in continuous bioprocessing.
Collapse
Affiliation(s)
- Amin Javidanbardan
- Department of Chemical Engineering, The Pennsylvania State University, University Park, PA 16802, USA
| | - Kevork Oliver Messerian
- Department of Chemical Engineering, The Pennsylvania State University, University Park, PA 16802, USA
| | - Andrew L Zydney
- Department of Chemical Engineering, The Pennsylvania State University, University Park, PA 16802, USA.
| |
Collapse
|
2
|
Dewar EA, Guterstam P, Holland D, Lindman S, Lundbäck P, Brito Dos Santos S, Wang SC, Swartz AR. Improved mRNA affinity chromatography binding capacity and throughput using an oligo-dT immobilized electrospun polymer nanofiber adsorbent. J Chromatogr A 2024; 1717:464670. [PMID: 38310705 DOI: 10.1016/j.chroma.2024.464670] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2023] [Revised: 01/19/2024] [Accepted: 01/20/2024] [Indexed: 02/06/2024]
Abstract
Increased demand for mRNA-based therapeutics and improved in vitro transcription (IVT) yields have challenged the mRNA purification platform. Hybridization-affinity chromatography with an immobilized oligo-deoxythymidilic acid (oligodT) ligand is often used to capture mRNA through base pairing with the polyadenylated tail. Commercially available oligodT matrices include perfusive cross-linked poly(styrene-divinylbenzene) 50 µm POROS™ chromatography resin beads and convective polymethacrylate CIMmultus® monolithic columns consisting of 2 µm interconnected channels. POROS™ columns may be limited by poor mass transfer for larger mRNAs and slow flowrates, while monoliths can operate at higher flowrates but are limited by modest binding capacity. To enable both high flowrates and binding capacity for mRNA of all lengths, prototype chromatography media was developed by Cytiva using oligodT immobilized electrospun cellulose nanofibers (Fibro™) with a 0.3-0.4 µm pore size. In this work, four polyadenylated mRNAs ranging from ∼1900-4300 nucleotides were used to compare the dynamic binding capacity (DBC) of Fibro™, POROS® and CIMmultus® columns as a function of residence time and binding buffer compositions. Fibro™ improved the DBC ∼2-4-fold higher than CIMmultus® and ∼2-13-fold higher than POROS™ across all residence times, mRNA length, and binding matrix compositions tested. CIMmultus® DBC was least dependent on residence time and mRNA size, while both Fibro™ and POROS™ DBC increased at slower flowrates and with shorter mRNA. Surprisingly, inverse size exclusion (ISE) experiments showed that POROS™ was not limited by diffusion and POROS™ along with CIMmultus® demonstrate higher mRNA permeation however the Fibro™ prototype is not in the final configuration. Lastly, IVT reaction products were subjected to purification and oligodT elution product yield, quality, and purity were consistent across the three matrices investigated. These results highlight the benefits of high DBC and equivalent product profiles offered by the oligodT Fibro™ prototype compared to commercially available oligodT media.
Collapse
Affiliation(s)
- Emily A Dewar
- Process Research and Development, Merck & Co., Inc., Rahway, NJ, United States.
| | | | - David Holland
- Analytical Research and Development,Merck & Co.,Inc., Rahway, NJ, United States
| | | | | | | | - Sheng-Ching Wang
- Process Research and Development, Merck & Co., Inc., Rahway, NJ, United States
| | - Andrew R Swartz
- Process Research and Development, Merck & Co., Inc., Rahway, NJ, United States
| |
Collapse
|
3
|
Nair A, Loveday KA, Kenyon C, Qu J, Kis Z. Quality by Digital Design for Developing Platform RNA Vaccine and Therapeutic Manufacturing Processes. Methods Mol Biol 2024; 2786:339-364. [PMID: 38814403 DOI: 10.1007/978-1-0716-3770-8_16] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/31/2024]
Abstract
Quality by digital design (QbDD) utilizes data-driven, mechanistic, or hybrid models to define and optimize a manufacturing design space. It improves upon the QbD approach used extensively in the pharmaceutical industry. The computational models developed in this approach identify and quantify the relationship between the product's critical quality attributes (CQAs) and the critical process parameters (CPPs) of unit operations within the manufacturing process. This chapter discusses the QbDD approach in developing and optimizing unit operations such as in vitro transcription, tangential flow filtration, affinity chromatography, and lipid nanoparticle (LNP) formulation in mRNA vaccine manufacturing. QbDD can be an efficient framework for developing a production process for a disease-agnostic product that requires extensive experimental and model-based process-product interaction characterization during the early process development phase.
Collapse
Affiliation(s)
- Adithya Nair
- Department of Biological and Chemical Engineering, University of Sheffield, Sheffield, UK
| | - Kate A Loveday
- Department of Biological and Chemical Engineering, University of Sheffield, Sheffield, UK
| | - Charlotte Kenyon
- Department of Biological and Chemical Engineering, University of Sheffield, Sheffield, UK
| | - Jixin Qu
- Department of Biological and Chemical Engineering, University of Sheffield, Sheffield, UK
| | - Zoltán Kis
- Department of Biological and Chemical Engineering, University of Sheffield, Sheffield, UK.
- Department of Chemical Engineering, Imperial College London, London, UK.
| |
Collapse
|
4
|
Megušar P, Miklavčič R, Korenč M, Ličen J, Vodopivec T, Černigoj U, Štrancar A, Sekirnik R. Scalable multimodal weak anion exchange chromatographic purification for stable mRNA drug substance. Electrophoresis 2023; 44:1978-1988. [PMID: 37828276 DOI: 10.1002/elps.202300106] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2023] [Revised: 09/15/2023] [Accepted: 09/18/2023] [Indexed: 10/14/2023]
Abstract
Messenger RNA (mRNA) has emerged as a modality with immense therapeutic potential. Recent innovations in production process of mRNA call for procedures to isolate pure mRNA drug substance (DS) with high yield, high capacity, scalability, and compatibility with GMP production systems. Novel RNA modalities, such as circular RNA (circRNA), have further driven the need for non-affinity capture possibilities which are already widely used in the biopharmaceutical industry, for example, in monoclonal antibody processing. The principle that multimodal ion exchange/hydrogen bonding chromatography can be used to separate mRNA from in vitro transcription components has recently been demonstrated. Here, we apply and refine this approach to be suitable for scalable purification of multiple mRNA constructs with sufficient yields, purity, and stability, for use in mRNA production process. Binding capacity of the PrimaS-modified monolithic chromatographic column for mRNA enabled up to 7 mg/mL product isolation in a single chromatographic run, with 98% recovery and room temperature stability of the eGFP mRNA demonstrated for up to 28 days. This approach is independent of construct size or the presence of polyadenylic acid tail and is applicable for capture of a wide variety of RNAs, including mRNA, self-amplifying RNA, circRNA, and with optimization also smaller RNAs such as transfer RNA and others.
Collapse
Affiliation(s)
| | - Rok Miklavčič
- Sartorius BIA Separations d.o.o., Ajdovščina, Slovenia
| | - Matevž Korenč
- Sartorius BIA Separations d.o.o., Ajdovščina, Slovenia
| | - Jure Ličen
- Sartorius BIA Separations d.o.o., Ajdovščina, Slovenia
| | | | - Urh Černigoj
- Sartorius BIA Separations d.o.o., Ajdovščina, Slovenia
| | - Aleš Štrancar
- Sartorius BIA Separations d.o.o., Ajdovščina, Slovenia
| | - Rok Sekirnik
- Sartorius BIA Separations d.o.o., Ajdovščina, Slovenia
| |
Collapse
|
5
|
Youssef M, Hitti C, Puppin Chaves Fulber J, Kamen AA. Enabling mRNA Therapeutics: Current Landscape and Challenges in Manufacturing. Biomolecules 2023; 13:1497. [PMID: 37892179 PMCID: PMC10604719 DOI: 10.3390/biom13101497] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2023] [Revised: 10/05/2023] [Accepted: 10/06/2023] [Indexed: 10/29/2023] Open
Abstract
Recent advances and discoveries in the structure and role of mRNA as well as novel lipid-based delivery modalities have enabled the advancement of mRNA therapeutics into the clinical trial space. The manufacturing of these products is relatively simple and eliminates many of the challenges associated with cell culture production of viral delivery systems for gene and cell therapy applications, allowing rapid production of mRNA for personalized treatments, cancer therapies, protein replacement and gene editing. The success of mRNA vaccines during the COVID-19 pandemic highlighted the immense potential of this technology as a vaccination platform, but there are still particular challenges to establish mRNA as a widespread therapeutic tool. Immunostimulatory byproducts can pose a barrier for chronic treatments and different production scales may need to be considered for these applications. Moreover, long-term storage of mRNA products is notoriously difficult. This review provides a detailed overview of the manufacturing steps for mRNA therapeutics, including sequence design, DNA template preparation, mRNA production and formulation, while identifying the challenges remaining in the dose requirements, long-term storage and immunotolerance of the product.
Collapse
Affiliation(s)
| | | | | | - Amine A. Kamen
- Department of Bioengineering, McGill University, Montreal, QC H3A 0G4, Canada; (M.Y.); (C.H.); (J.P.C.F.)
| |
Collapse
|
6
|
Development and scale-up of oligo-dT monolithic chromatographic column for mRNA capture through understanding of base-pairing interactions. Sep Purif Technol 2023. [DOI: 10.1016/j.seppur.2022.122320] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|